Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

导出原文传递

翻译打印收藏纠错

作者： Falchook, Gerald S. ^[1] ; Wheler, Jennifer J. ^[2] ; Naing, Aung ^[3] ; Piha-Paul, Sarina A. ; Fu, Siqing ; Tsimberidou, Apostolia M. ; Hong, David S. ; Janku, Filip ; Zinner, Ralph ; Jiang, Yunfang ; Huang, Mei ; Lin, Quan ; Parkhurst, Kristin ; Kurzrock, Razelle

作者单位： Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA ^[1] HealthONE, Sarah Cannon Res Inst, Presbyterian St Lukes Med Ctr, Denver, CO 80218 USA ^[2] Univ Calif San Diego, Moores Canc Ctr, Ctr Personalized Canc Therapy, San Diego, CA 92093 USA ^[3]

关键词 Bevacizumab Sorafenib VEGF VEGFR Angiogenesis

发布时间 2015-04-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Investigational New Drugs

2015年33卷1期

215-224页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

Investigational New Drugs

相似文献

Investigational New Drugs

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

Investigational New Drugs

相似文献

Investigational New Drugs

相关期刊

检索历史清除